A study reveals that repeated anti-VEGF injections for AMD do not alter retinal vascular metrics over time, ensuring treatment stability.

In this Healio Video Perspective from the ARVO meeting, Justis P. Ehlers, MD, shares results from the phase 1 HELIOS study investigating OTX-TKI for the treatment of nonproliferative diabetic ...

Jiarui Nie, a postdoctoral researcher at the National Institutes of Health, is exploring how gold nanoparticles injected into ...

Intravitreal aflibercept 2 mg regimen is linked with long-term visual acuity improvements in macular edema following CRVO.

IDE Group recently unveiled OKO, its new ophthalmic auto-injector for improving drug delivery precision and efficiency.

This retrospective case series involved a review of medical records at a single tertiary care center. Charbel Issa and ...

Seven months after the FDA approved the reintroduction of Roche's eye implant Susvimo, the US agency has expanded its approved use to include treatment for diabetic macular edema, the primary ...

The primary treatment for DME includes intravitreal injections, where the eye is numbed with drops before injecting ...

Regeneron (REGN) stock drops as the company's Q1 2025 results miss forecasts amid disappointing sales from its blockbuster ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

At the J.P. Morgan Healthcare Conference in January, Regeneron CEO Leonard Schleifer said that the company’s new formulation of eye disease treatment Eylea needed “a few more arrows in its ...

The FDA made two de­ci­sions on Re­gen­eron’s best-sell­ing drugs Fri­day, hand­ing down one ap­proval and one re­jec­tion. The ap­proval came for Dupix­ent, the megablock­buster Re ...